Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Recursion Pharmaceuticals Inc (RXRX) vs Uranium Energy Corp (UEC) Price & Performance

Recursion Pharmaceuticals IncTrade
Uranium Energy CorpTrade

Price performance (Past 24H)

Key statistics

Recursion Pharmaceuticals Inc vs Uranium Energy Corp — how do they compare? Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B), while Uranium Energy Corp trades at $11.52 (market cap $5.63B). The key difference: Uranium Energy Corp is far larger — about 3.2× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.

RXRXUEC
Market Cap
$1.78B$5.63B
Sector
HealthEnergy
52-Week High
$6.79$20.14
52-Week Low
$2.84$9.04
Enterprise Value
$1.30B$5.14B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Recursion Pharmaceuticals Inc

RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.

Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.

Uranium Energy Corp

UEC trades at $11.26, up 4.65% in the last 24 hours, with a bullish technical signal from moving averages. The company reported a net loss of $87.66 million in 2025, with revenue of $66.84 million, and faces profitability challenges with a negative net income margin of -513.24%. Recent news highlights optimism around nuclear energy growth, but financial performance remains under pressure.

Outlook is mixed: strong analyst buy ratings (87.5%) and sector tailwinds support potential, but persistent losses, high P/S ratio of 265.97, and execution risks pose significant challenges. Investors should weigh the speculative growth narrative against fundamental weaknesses and cash flow concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX

About Uranium Energy Corp

Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.

Read more on UEC